SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-246357
Filing Date
2022-09-16
Accepted
2022-09-16 16:02:57
Documents
15
Period of Report
2022-09-14
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d386189d8k.htm   iXBRL 8-K 32916
2 EX-1.1 d386189dex11.htm EX-1.1 215774
3 EX-5.1 d386189dex51.htm EX-5.1 5980
7 GRAPHIC g386189dsp0048.jpg GRAPHIC 3615
  Complete submission text file 0001193125-22-246357.txt   445193

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA akro-20220914.xsd EX-101.SCH 2858
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE akro-20220914_lab.xml EX-101.LAB 17996
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE akro-20220914_pre.xml EX-101.PRE 11263
9 EXTRACTED XBRL INSTANCE DOCUMENT d386189d8k_htm.xml XML 3367
Mailing Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080
Business Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080 650-487-6488
Akero Therapeutics, Inc. (Filer) CIK: 0001744659 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38944 | Film No.: 221248089
SIC: 2834 Pharmaceutical Preparations